Skip to main content
Corrigendum: Clinical efficacy, safety and tolerability of a new subcutaneous immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the treatment of patients with primary immunodeficiencies
Abstract
[This corrects the article DOI: 10.3389/fimmu.2019.00040.].
Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.